enrasentan has been researched along with Blood Pressure, High in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brooks, DP; Brooks, SA; Eybye, M; Hieble, JP; Jugus, MJ; McCafferty, GP; Pullen, M; Ventre, J; Westfall, TD | 1 |
| Aiyar, N; Anderson, KM; Barone, FC; Coatney, RW; Nelson, AH; Ohlstein, EH; Olzinski, AR; Willette, RN; Woods, T | 1 |
| Bellini, G; Bernobich, E; Bertola, G; Bonavita, M; Cosenzi, A; Trevisan, R | 1 |
3 other study(ies) available for enrasentan and Blood Pressure, High
| Article | Year |
|---|---|
Effect of endothelin on bladder contraction: potential role in bladder hyperactivity.
Topics: Animals; Benzofurans; Carboxylic Acids; Dose-Response Relationship, Drug; Endothelins; Hypertension; Indans; Infusions, Intravenous; Male; Muscle Contraction; Propionates; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Urinary Bladder; Urination; Urination Disorders | 2003 |
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Carboxylic Acids; Endothelin Receptor Antagonists; Heart Rate; Hypertension; Hypertrophy, Left Ventricular; Indans; Male; Myocardium; Protein Precursors; Rats; Rats, Inbred SHR; Survival Rate; Ventricular Remodeling | 2001 |
Antihypertensive treatment with enrasentan (SB217242) in an animal model of hypertension and hyperinsulinemia.
Topics: Animals; Blood Pressure; Body Weight; Carboxylic Acids; Collagen; Dietary Carbohydrates; Disease Models, Animal; Endothelin Receptor Antagonists; Fructose; Hyperinsulinism; Hypertension; Indans; Kidney; Male; Myocardium; Rats; Rats, Inbred WKY | 2002 |